ArticlePloS one2009
Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 14 syntheses or guidelines pooled it.
- Six polymorphisms in the lncRNA H19 gene and the risk of cancer: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- Systematic evaluation of the association between a missense variant in XRCC3 gene splicing site and the pathogenesis of ovarian cancer.Bioscience reports · 2023Pooled it
- The association between single nucleotide polymorphisms and ovarian cancer risk: A systematic review and network meta-analysis.Cancer medicine · 2023Pooled it
- Association of the PROGINS PgR polymorphism with susceptibility to female reproductive cancer: A meta-analysis of 30 studies.PloS one · 2022Pooled it
- The association between XRCC3 rs1799794 polymorphism and cancer risk: a meta-analysis of 34 case-control studies.BMC medical genomics · 2021Pooled it
- Pooled it
- Pooled it
- Association between genetic polymorphisms of long noncoding RNA H19 and cancer risk: a meta-analysis.Journal of genetics · 2019Pooled it
- Significant association between lncRNA H19 polymorphisms and cancer susceptibility: a meta-analysis.Oncotarget · 2017Pooled it
- Association between the BRCA2 rs144848 polymorphism and cancer susceptibility: a meta-analysis.Oncotarget · 2017Pooled it
- Quantitative assessment of polymorphisms in H19 lncRNA and cancer risk: a meta-analysis of 13,392 cases and 18,893 controls.Oncotarget · 2016Pooled it
- Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk.BioMed research international · 2014Pooled it
- Analyze association of the progesterone receptor gene polymorphism PROGINS with ovarian cancer risk.Molecular biology reports · 2013Pooled it
- Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.Breast cancer research and treatment · 2013Trial
- SEPTIN12 c.474 G > A polymorphism as a risk factor in teratozoospermic patients.Molecular biology reports · 2021Article
- Association of XRCC3 18067 C>T (Thr241Met) polymorphism with risk of cervical and ovarian cancers: A systematic review and meta-analysis.Interventional medicine & applied science · 2020Review
- Low-penetrance susceptibility variants and postmenopausal oestrogen receptor positive breast cancer.Journal of genetics · 2020Article
- Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk.Archives of medical science : AMS · 2020Article
- Association of lncRNAGenes · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundRecent studies have identified several single nucleotide polymorphisms (SNPs) in the population that are associated with variations in the risks of many different diseases including cancers such as breast, prostate and colorectal. For ovarian cancer, the known highly penetrant susceptibility genes (BRCA1 and BRCA2) are probably responsible for only 40% of the excess familial ovarian cancer risks, suggesting that other susceptibility genes of lower penetrance exist.
methodsWe have taken a candidate approach to identifying moderate risk susceptibility alleles for ovarian cancer. To date, we have genotyped 340 SNPs from 94 candidate genes or regions, in up to 1,491 invasive epithelial ovarian cancer cases and 3,145 unaffected controls from three different population based studies from the UK, Denmark and USA.
resultsAfter adjusting for population stratification by genomic control, 18 SNPs (5.3%) were significant at the 5% level, and 5 SNPs (1.5%) were significant at the 1% level. The most significant association was for the SNP rs2107425, located on chromosome 11p15.5, which has previously been identified as a susceptibility allele for breast cancer from a genome wide association study (P-trend = 0.0012). When SNPs/genes were stratified into 7 different pathways or groups of validation SNPs, the breast cancer associated SNPs were the only group of SNPs that were significantly associated with ovarian cancer risk (P-heterogeneity = 0.0003; P-trend = 0.0028; adjusted (for population stratification) P-trend = 0.006). We did not find statistically significant associations when the combined data for all SNPs were analysed using an admixture maximum likelihood (AML) experiment-wise test for association (P-heterogeneity = 0.051; P-trend = 0.068).
conclusionThese data suggest that a proportion of the SNPs we evaluated were associated with ovarian cancer risk, but that the effect sizes were too small to detect associations with individual SNPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.